The AIRQ effectively identifies asthma exacerbation risk at 3 months and 12 months among patients with varying levels of asthma severity.

Please provide your email address to receive an email when new articles are posted on . Moderate exacerbations shared similar characteristics with severe exacerbations. Lung function, limitations and ...

In the spring, patients with chronic obstructive pulmonary disease (COPD) may develop a common acute respiratory viral infection (ARVI) into a serious exacerbation. On April 20, Sergey Avdeev, MD, ...

Patients with acute COPD exacerbations are seen frequently in the emergency department (ED). Acute exacerbations are associated with significant morbidity, mortality and health care expenditures.

Please provide your email address to receive an email when new articles are posted on . DENVER — The use of several common antibiotics led to exacerbation of myasthenia gravis in a small cohort of ...

Tozorakimab is an investigational monoclonal antibody designed to bind and inhibit interleukin-33 (IL-33), an alarmin cytokine. This targeted approach is expected to reduce airway inflammation and ...

A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy, ...

Panelists discuss how bacterial infections, environmental triggers, and microbiome imbalances cause bronchiectasis exacerbations, leading to increased cough, phlegm, fatigue, and hemoptysis.

Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab. HealthDay News — For patients with chronic obstructive pulmonary disease (COPD) with a history of ...

August 22, 2012 — A new application of a drug that was approved in 1996 and has been widely used since significantly decreased the frequency of exacerbations and increased the time to first ...

AstraZeneca’s tozorakimab has shown benefit in a third Phase III trial in chronic obstructive pulmonary disorder (COPD). In ...

Highly symptomatic bronchiectasis patients have increased exacerbation risks, regardless of previous exacerbation history or disease severity. Current guidelines do not recommend preventive treatments ...